The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) frequently presents as advanced stage with poor prognosis and high mortality. Systemic treatment is the treatment of choice for advanced disease. In 2007, the first multi-kinase inhibitor (MKI) sorafenib was approved and shown to modestly prolong overall survival (OS)....
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Korean Liver Cancer Association
2023-09-01
|
| Saila: | Journal of Liver Cancer |
| Gaiak: | |
| Sarrera elektronikoa: | http://www.e-jlc.org/upload/pdf/jlc-2023-07-17.pdf |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|